Dublin, Jan. 09, 2024 (GLOBE NEWSWIRE) -- The 'Bile Duct Cancer Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region' report has been added to ResearchAndMarkets.com's offering.The global bile duct cancer treatment market is expected to witness robust growth between 2024 and 2031.

都柏林，2024年1月9日（环球通讯社）--“胆管癌治疗市场-2031年全球行业分析、规模、份额、增长、趋势和预测-按产品、技术、等级、应用、最终用户、地区”报告已添加到ResearchAndMarkets.com的产品中。预计2024年至2031年间，全球胆管癌治疗市场将强劲增长。

However, the market faces significant challenges, primarily driven by cost-related factors.Rising Incidences of Bile Duct Cancer in North AmericaBile duct cancer and liver cancer cases have seen a concerning increase in North America in recent years. It is estimated that approximately 6,000 individuals are diagnosed with bile duct cancer each year in the United States.

然而，市场面临着重大挑战，主要是由成本相关因素驱动的。北美胆管癌发病率上升近年来，北美胆管癌和肝癌病例有所增加。据估计，美国每年约有6000人被诊断出患有胆管癌。

Alarmingly, the majority of those affected fall within the age group of 70 to 75 years.Bile Duct Cancer Treatment Market DynamicsAdvancements in endoscopic imaging techniques and minimally-invasive high-tech stone retrieval products have emerged as key drivers for the growth of the pancreatic and bile duct stone management market.

令人担忧的是，大多数受影响的人属于70至75岁的年龄组。胆管癌治疗市场动态内镜成像技术和微创高科技结石回收产品的进步已成为胰腺和胆管结石管理市场增长的关键驱动因素。

This segment is expected to witness a double-digit CAGR in the coming years.A notable observation is that Asians are more prone to contracting bile duct cancers compared to non-Hispanic blacks and whites. Currently, the primary line of therapy for bile duct cancers involves chemotherapy, and it is expected to maintain the largest market share in the foreseeable future as alternative treatment methods take time to gain acceptance.The U.S.

预计未来几年，这一细分市场的复合年增长率将达到两位数。一个值得注意的观察结果是，与非西班牙裔黑人和白人相比，亚洲人更容易患胆管癌。目前，胆管癌的主要治疗方法涉及化疗，预计在可预见的未来将保持最大的市场份额，因为替代治疗方法需要时间才能获得认可。美国。

Food and Drug Administration (FDA) has initiated accelerated approvals to expedite the introduction of these therapies into the bile duct cancer treatment market, aiming to provide patients with faster access to treatments.Cost as a Restraining FactorOne significant.

美国食品和药物管理局（FDA）已启动加速批准，以加速将这些疗法引入胆管癌治疗市场，旨在为患者提供更快的治疗机会。成本是一个重要的制约因素。